4.3.2022 06:51:24 CET | Demant A/S |
Intern viden
Selskabsmeddelelse nr. 2022-05 4. marts 2022
Investering i førende vækstplatform i Kina
Demant har gennemført købet af 20 % af aktierne i ShengWang, som er et førende netværk af høreklinikker i Kina med omkring 500 butikker over hele landet. Investeringen gør det muligt for Demant at styrke sin position yderligere i det store, hurtigtvoksende kinesiske marked for høreapparater, hvor ShengWang har store ambitioner om fortsat ekspansion. Med en stærk ledelse, en veletableret organisation og skalérbare processer udgør ShengWang en fremragende vækstplatform i de næste mange år.
Demant og ShengWang arbejder i tæt fællesskab på at gennemføre en transaktion vedrørende købet af de resterende 80 % af ShengWang inden udgangen af H1 2022, hvor detaljerne omkring den finansielle effekt af transaktionen vil blive offentliggjort.
ShengWang blev grundlagt i 1998 og har i mange år – og især efter introduktionen af Philips Hearing Solutions – været en værdsat samarbejdspartner for Demant-koncernen takket være stærke relationer med vores Hearing Aids-forretningsområde. I dag har ShengWang mere end 1.300 medarbejdere, der servicerer det hurtigtvoksende kinesiske marked for høreomsorg, som forventes at opleve tocifrede årlige vækstrater i de næste mange år som følge af den demografiske udvikling og en gradvist stigende penetrationsrate.
Som en del af investeringen i ShengWang er Niels Wagner, President for Demants Hearing Care-forretningsområde, indtrådt i selskabets bestyrelse.
Isoleret set vil det gennemførte køb af 20 % af aktierne i ShengWang kun have meget begrænset finansiel indvirkning på koncernen, hvorfor koncernens forventninger til 2022 er uændrede. Den planlagte fuldstændige akkvisition af ShengWang vil medføre fuld finansiel konsolidering, og som nævnt ovenfor vil den finansielle effekt af en sådan konsolidering blive offentliggjort, når transaktionen er gennemført.
Yderligere information:
Søren Nielsen, koncernchef og adm. direktør
Telefon +45 3917 7300
www.demant.com
Øvrige kontaktpersoner:
René Schneider, CFO
Mathias Holten Møller, Head of Investor Relations
Peter Pudselykke, Investor Relations Officer
Trine Kromann-Mikkelsen, VP Corporate Communications and Relations
Om Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Vedhæftninger
2022-05 Investering i førende vækstplatform i Kina.pdf
4.3.2022 06:51:24 CET | Demant A/S |
Inside information
Company announcement no 2022-05 4 March 2022
Investment in leading growth platform in China
Demant has completed the acquisition of 20% of the shares in ShengWang, a leading network of hearing aid clinics in China with around 500 shops across the country. The investment allows Demant to further strengthen its position in the large, fast-growing Chinese hearing aid market where ShengWang has high ambitions for continued expansion. With a strong leadership team, a proven organisation and scalable processes, ShengWang offers an excellent growth platform for the next many years.
Demant and ShengWang are working in close collaboration to complete a transaction regarding the acquisition of the remaining 80% of ShengWang before the end of H1 2022 at which point details of the financial impact of the transaction will be disclosed.
ShengWang was founded in 1998 and has for several years – and particularly following the introduction of Philips Hearing Solutions – been a valued partner of the Demant Group thanks to a strong relationship with our Hearing Aids business. Today, ShengWang has more than 1,300 employees serving the fast-growing Chinese market for hearing care, which is expected to see double-digit annual growth rates in the next many years due to demographic developments and a gradually increasing penetration rate.
As part of the investment in ShengWang, Niels Wagner, President of Demant’s Hearing Care business, has joined the company’s board of directors.
In itself, the completed acquisition of 20% of the shares in ShengWang will only have a very limited financial impact on the Group, and the Group’s outlook for 2022 thus remains unchanged. Completion of the planned full acquisition of ShengWang will entail full financial consolidation, and as stated above, the financial impact of such consolidation will be disclosed upon closing of the transaction.
Further information:
Søren Nielsen, President & CEO
Phone +45 3917 7300
www.demant.com
Other contacts:
René Schneider, CFO
Mathias Holten Møller, Head of Investor Relations
Peter Pudselykke, Investor Relations Officer
Trine Kromann-Mikkelsen, VP Corporate Communications and Relations
About Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Attachments
2022-05 Investment in leading growth platform in China.pdf
